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HER3, HER4) to form homodimers or heterodimers, causing the activation of the EGFR tyrosine kinase, which in turn activates the mitogen-activated protein kinase and kinase signaling pathways, and fi nally leads to cell proliferation, differentiation, angiogenesis, invasion and metastasis, as well as motility and survival ( 4 , 5 ) . Meanwhile, EGFR overexpression in breast cancer is inversely correlated with estrogen receptor (ER) expression and is directly correlated with advanced tumor stage, resistant to standard therapies (hormonal therapy, chemotherapy, and radiation) ( 6 -9 ). Therefore, abnormalities and dysfunction of EGFR are involved in various aspects of carcinogenesis and tumor progression ( 10 ), and consequently EGFR becomes an excellent target for diagnosis and anti-tumor therapy ( 11 , 12 ) . EGFR-targeted therapeutic agents, including specifi c antibodies directed against its ligand-binding domain and small molecules inhibiting its tyrosine kinase activity, are either under clinical trial or have already been approved for clinical treatment ( 4, 9 , 11 , 13 ) . However, there are few reliable methods to monitor the intended target (e.g., EGFR expression) and predict the response to therapy or gauge treatment response over time ( 14 ) , which is a major hindrance to further developing these specifi cally targeted and highly effi cient therapies.
Noninvasive imaging techniques for measuring tumor physiologic parameters on the molecular level are being developed ( 15 ) , which may facilitate repetitive and quantitative imaging of EGFR before or during a course of treatment. As new cancer therapeutic agents more specifi cally target tumor cell signaling pathways, such molecular imaging technology is becoming increasingly important ( 16 ). Pretreatment targeted imaging of particular molecules could be used to help physicians to identify patients who are likely to benefi t from targeted therapies. During the course of treatment, receptor-specifi c imaging could also assist early assessment of therapeutic target inhibition before alterations in tumor size become apparent ( 17 ).
Among the different imaging technologies being used to display molecular events, near-infrared (NIR) fl uorescence optical imaging, using neither ionizing radiation nor radioactive materials, is particularly promising ( 18 ). Although depth penetration is one major limiting factor for in vivo optical imaging, the tissue penetration of light is substantially increased (from millimeters to centimeters) using NIR probes, as the absorption by water and hemoglobin is relatively low in the NIR spectral window (650-900-nm "diagnostic window") ( 19 ). Thus, it enables the imaging of tumors within tissue, such as breast tissue ( 17 ). NIR fl uorescent dye Cy5.5 has proven to be a promising contrast agent for the in vivo demarcation of tumors by several groups ( 17, 20 -23 ) . Here, we chose the widely used Cy5.5 dye for our optical imaging studies. Erbitux was the fi rst FDA-approved anti-EGFR monoclonal antibody drug with anticancer activity on the market ( 24 ). It selectively binds to the external domain of the receptor with affi nity comparable to the natural ligand (K d = 1 nM) and competes with EGF binding ( 23 ).
The aim of this study was to investigate whether in vivo NIR fl uorescence imaging mediated by an Erbitux-Cy5.5 conjugate could be used to discriminate EGFR expression level in nude mice models implanted with EGFR-overexpressing, estrogen-independent, highly invasive, and metastatic human breast MDA-MB-231 cells and low-EGFR-expressing, estrogendependent, poorly invasive, and non-metastatic MCF-7 cells, each of which represents a clinically relevant subtype of human breast cancer ( 25 , 26 ) .
Material and Methods
Fluorochrome probe generation Cy5.5 dye molecules with monofunctional N -hydroxysuccinimide (NHS) ester (Cy5.5-NHS; GE Healthcare, Piscataway, N.J., USA) were coupled to Erbitux (ImClone Systems, Branchburg, N.J., USA) according to a protocol from the previous literature, with modifi cations ( 22 ). Briefl y, Erbitux (10 mg, 66.7 nmol) dissolved in 500 μl of 0.1 mol/l sodium borate (Na 2 B 4 O 7 ) buffer (pH 8.3) was mixed with Cy5.5-NHS (0.4 mg, 355 nmol) in H 2 O (100 μl) in the dark at 4°C. After stirring for 2 hours in the dark at 4°C, the reaction was quenched by adding 100 μl of 5% acetic acid (HOAc). The labeled antibody was isolated by a PD-10 disposable column (GE Healthcare, Piscataway, N.J., USA). The peak containing the Erbitux-Cy5.5 conjugate was collected, lyophilized, and re-dissolved in saline at a concentration of 1 mg/ml, and stored in the dark at -20°C until use. To measure and characterize the absorption and emission spectra of Erbitux-Cy5.5, identical dye concentrations of Erbitux-Cy5.5 and Cy5.5 were put in a quartz pool. Maximum absorption and emission wavelengths were determined in the scope of 200-800 nm, under a Cary-Eclipse 4000 ultraviolet-visible light fl uorospectrophotometer (Varian, Inc., Palo Alto, Calif., USA).
Cell culture
Human breast cancer cells that express a high level of EGFR (MDA-MB-231) and a low level of EGFR (MCF-7) were obtained from the China Science Institute Cell Bank (Shanghai, China) and cultured, following the instructions from the American Type Culture Collection (ATCC). Briefl y, MDA-MB-231 cells were cultured in Leibovitz's L-15 medium (Invitrogen, Carlsbad, Calif., USA), while MCF-7 cells were cultured in Dulbecco's minimum essential medium (DMEM; Sigma Chemical Co., St. Louis, Mo., USA), with 10% fetal bovine serum (FBS; Gibco BRL, Cleveland, Ohio, USA), 100 U penicillin, 0.1 μg streptomycin, and 2 mmol/l L-glutamax, in an humidifi ed incubator maintained at 37°C with 5% CO 2 .
In vitro receptor binding studies The binding of Erbitux-Cy5.5 to EGFR was assessed by using fl ow cytometry. Briefl y, 2 ϫ 10 6 MDA-MB-231 and 2 ϫ 10 6 MCF-7 cells were incubated in suspension with 5 nM Erbitux-Cy5.5 for 30 min at 37°C in a total volume of 150 μl, respectively, protected from light and then centrifugally elutriated twice in phosphate buffered solution (PBS, pH 7.2, 10 mM). Fluorescence intensity was assessed with fl ow cytometry (FACSort; Becton Dickinson, Franklin Lakes, N.J., USA). For competitive inhibition of probe binding, 5-nM-labeled probes, along with 500 nM of Erbitux, were added to the MDA-MB-231 and MCF-7 cells, respectively, by using the same incubation and washing conditions, followed by fl ow cytometric analysis. As the blank control, PBS was added to each assay group. All experiments were carried out in triplicate, and the mean values were calculated. Fluorescence microscopy (with an Olympus confocal microscope outfi tted with NIR diode sources and fi lters) of probe-stained tumor cells and the specifi c antibody block experiment were also performed for visual confi rmation of the intake of Erbitux-Cy5.5 in MDA-MB-231 and MCF-7 cells. DAPI was used to stain cell nuclei. In the microscopic images, Erbitux-Cy5.5 was pseudocolored red (emission at 680-710 nm), while DAPI was pseudocolored blue (emission at 461 nm).
Tumor xenografts
All mouse studies were conducted in accordance with an Institute of Animal Care and Use Committee (IACUC)-approved protocol. Female athymic nude mice (BALB/c-nu/nu, 4-6 weeks old, 18-22 g) from Vital River Laboratories (National Science Institute, Beijing, China) were housed fi ve per cage and provided with sterilized pellet chow and sterilized water. Animals were maintained in a pathogen-free mouse colony at the Tumor Treatment and Prevention Institute (TTPI) at the Harbin Medical University (Harbin, China). MDA-MB-231 and MCF-7 cells were treated with trypsin when near confl uence and harvested. Cells were centrifuged at 1200 rpm for 5 min and re-suspended in sterile culture medium. The suspension (5 ϫ 10 6 cells/0.2 ml) was injected into the mouse left chest mammary gland fat pad. When the tumors reached 0.4 to 0.6 cm in diameter (14-21 days after implant), the tumor-bearing mice were subjected to in vivo imaging studies.
In vivo optical imaging system The mice were imaged with an eXplore Optix timedomain fl uorescence imaging system (ART/GE Healthcare, Saint-Laurent, Quebec, Canada) to detect Erbitux-Cy5.5 in tumors, which was a temperaturecontrolled, light-tight box with a cryogenically cooled back-illuminated digital charge-coupled device (CCD) camera. The system featured a 667-nm pulse laser for excitation, with a 710-nm bandpass fi lter on the emission side. Image acquisition was accomplished using time-domain Molecular Imager software, and the obtained images were stored in the bmp image fi le format. All image stacks were acquired by using identical laser power (2 μW), integration time (1 s/ point), resolution rate, window, and level settings. Data processing and analysis was accomplished using eXplore OPTX-optView software (ART/GE Healthcare, Saint-Laurent, Quebec, Canada).
In vivo NIR optical imaging
For in vivo testing of the specifi city of Erbitux-Cy5.5, mice bearing MDA-MB-231 ( n = 5) and MCF-7 tumors (n = 5) were anesthetized with an intraperitoneal (i.p.) injection of 50 mg/kg pentobarbital and then intravenously (i.v.) injected with 0.2 nmol per mouse Erbitux-Cy5.5 via the tail vein. For the blocking study, 3 mg of Erbitux (20 nmol, 100-fold excess) was injected i.v. to each MDA-MB-231 ( n = 5) or MCF-7 mouse ( n = 5) 24 hours prior to the injection of 0.2 nmol Erbitux-Cy5.5. Whole-body fl uorescence images were then acquired every 30 min up to 6 hours post injection, and each mouse was imaged again at the 24-hour time point. At the end of the imaging studies, ex vivo fl uorescence images of the dissected tumor tissue and organs were obtained.
To observe the tumor clearance pattern of Erbitux-Cy5.5 in vivo, dynamic scans were acquired. Briefl y, MDA-MB-231 ( n = 5) and MCF-7 mice ( n = 5) were anesthetized with i.p. injection of pentobarbital and then i.v. injected with Erbitux-Cy5.5 (0.2 nmol/mouse). By using the white-light image as a guide, symmetric tumor and normal regions of interest (ROI) were designated in each mouse chest part. The local ROI imaging was performed every 10 min up to 6 hours post injection, and from 24 to 192 hours at intervals of every 24 hours.
In vitro probe binding studies by fl ow cytometry and confocal microscopy The Erbitux-Cy5.5 probe showed a 9.3-fold increase in binding to MDA-MB-231 compared with MCF-7 cells ( Fig. 1 A) . As measured according to fl uorescence intensity counts, the mean gated percentage of MDA-MB-231 was 69.0 Ϯ 2.5%, while MCF-7 was 7.4 Ϯ 1.8% ( n = 3, P Ͻ 0.001). At competitive receptor binding assay, probe binding was competitively inhibited by the addition of a 100-fold molar excess of unlabeled Erbitux in MDA-MB-231 and MCF-7 cells. Fluorescence microscopy of probe-stained MDA-MB-231 and MCF-7 tumor cells ( Fig. 1 B, fi rst and third rows) confi rmed the probe uptake to the cell endochylema. More intense cellular fl uorescence signal was observed in MDA-MB-231 cells than in MCF-7 cells, which is consistent with the higher levels of EGFR expression in MDA-MB-231 cells. Furthermore, the binding of the probe was completely blocked by anti-EGFR antibody Erbitux (100-fold excess, Fig. 1 B, second and fourth rows). These results further confi rmed that the receptor binding affi nity and specifi city of Erbitux in vitro was not affected by the conjunction.
In vivo fl uorescence imaging
Typical whole-body NIR fl uorescence images of athymic nude mice bearing orthotopic transplanted MDA-MB-231 and MCF-7 breast tumors verifi ed that the fl uorescent probe specifi cally accumulated in tumor regions 24 hours after intravenous injection ( Fig. 2 ) . The mean fl uorescence intensity in the tumor was 30,218 Ϯ 6583 arbitrary units (au) for MDA-MB-231 ( n = 5) and 18,908 Ϯ 1771 au for MCF-7 ( n = 5). To validate that the tumor accumulation of the fl uorescent dye complex was receptor specifi c, a blocking experiment was performed. An excess amount of Erbitux successfully reduced tumor contrast. The MDA-MB-231 tumor region mean fl uorescence intensity was 10,470 Ϯ 838 au (n = 5, P = 0.002), and that for MCF-7 was 9058 Ϯ 795 au ( n = 5, P Ͻ 0.001). Although the pretreatment with Erbitux resulted in a signifi cant decrease of tumor uptake of Erbitux-Cy5.5, the tumor accumulation was not completely blocked even with a higher dose of unlabeled Erbitux. The residual contrast is likely due to some nonspecifi c binding accumulated in the extracellular space; similar fi ndings have also been reported elsewhere ( 22 ).
To fully characterize the clearance pattern of Erbitux, the fl uorescence intensities in the tumor and the normal tissue were measured dynamically after the injection of Erbitux-Cy5.5 in MDA-MB-231 and MCF-7 tumor-bearing mice ( Fig. 3 ) . The mean fl uorescence intensities in the ROIs of MDA-MB-231
EGFR immunohistochemical (IHC) analysis
The immunohistochemistry for EGFR staining was determined by a two-step method. Formalin-fi xed, paraffi n-embedded tissue blocks were obtained from MDA-MB-231 and MCF-7 xenografts. Five-μm-thick tissue sections were cut, de-waxed, microwave pretreated, and incubated with 0.3% hydrogen peroxide in methanol for 30 min. After blocking to reduce nonspecifi c antibody binding, monoclonal rabbit anti-human EGFR antibody (1:150, COOH terminus; Santa Cruz Biotechnology, Santa Cruz, Calif., USA) was reacted with tissue sections at room temperature for 2 hours, followed by three washes with PBS. The sections were incubated with goat anti-rabbit IgG (Southern Biotechnology Associates, Birmingham, Ala., USA), and then reacted with streptoavidin-biotin peroxidase reagent (Histofi ne kit; Nichirei Biosciences Inc., Tokyo, Japan). Finally, diaminobenzidine (DAB) and 1% hydrogen peroxidase were applied as chromogen, counterstained with hematoxylin.
Statistical analysis
Standardized fl uorescence values were calculated by dividing the fl uorescence within the ROI by the value of the ROI area. Data were presented as means Ϯ standard deviation. The mean value from each ROI was plotted as a function of time for up to 192 hours post injection. Statistical signifi cance was assessed by using repeated-measures analysis of variance to compare the mean fl uorescence values binding in different tumor and normal-tissue ROIs at different time points post injection. Independent (or adjusted independent) samples Student t test was used to compare the mean fl uorescence intensities of other measurement data. Nonparametric test (Mann-Whitney test) was used to compare the difference of IHC results. A statistical software package (SPSS 13.0; SPSS, Inc., Chicago, Ill., USA) was used for data analysis. Statistical signifi cance was assigned for P values Ϯ 0.05.
Results

Synthesis and characterization of fl uorochrome probe
Cy5.5 has a degree of labeling of 4.2 mol of dye per mole of protein, and the yield of the Erbitux-Cy5.5 conjugate was typically 68-70%, as calculated with ε 678 nm = 250,000 M −1 cm −1 . The excitation and emission wave spectra showed that the maximum excitation/emission wavelengths for the Erbitux-Cy5.5 conjugate were 674/697 nm and for Cy5.5 were 674/712 nm, suggesting that the fl uorescence property of Cy5.5 was not affected by conjugation to Erbitux. uptake was 1.65-fold higher in the MDA-MB-231 tumor than in the MCF-7 tumor ( P Ͻ 0.001). The different slope rates indicated that the average probe uptake rate in the MDA-MB-231 tumors ( Fig. 3 B) was higher than in the MCF-7 tumors ( Fig. 3 D) .
EGFR IHC analysis
Upregulation of EGFR in the tumor region, relative to normal surrounding tissues, permits the preferential and MCF-7 tumors were signifi cantly higher than in normal area, which varied with time ( n = 5, P Ͻ 0.001). In the MDA-MB-231 model, the maximum probe uptake fl uorescence intensity occurred at 4 hours post injection (39,000 Ϯ 1343 au) ( Fig. 3 B) , while in the MCF-7 model, the maximum probe uptake fl uorescence intensity occurred at 6 hours post injection (23,592 Ϯ 1673 au) and plateaued up to 72 h before being cleared out ( Fig. 3 D) . The maximum probe Fig. 1 . In vitro probe binding studies by fl ow cytometry and confocal microscopy. A. Flow cytometry results for MDA-MB-231 and MCF-7 cell lines incubation with ligand linked to a fl uorescent dye. Five nM Erbitux-Cy5.5 showed strong binding to EGFR-overexpressing MDA-MB-231 cells and weak binding to low-EGFR-expressing MCF-7 cells. B. Confocal differential interference contrast (DIC) and fl uorescence images of MDA-MB-231 and MCF-7 cells in the presence of Erbitux-Cy5.5. The fi rst and third rows display the results from the cells incubated with 5 nM Erbitux-Cy5.5. The second and fourth rows display cells pretreated with Erbitux before incubation with Erbitux-Cy5.5. All images were acquired under the same conditions and are displayed on the same scale (scale bar, 10 μm). rate and maximum fl uorescence intensity in the MDA-MB-231 tumors ( n = 5) was higher than in the MCF-7 tumors, which correlated well with the receptor density measured by the ex vivo immunohistochemical analysis.
Because of its high sensitivity and spatial resolution, optical imaging technology with cancer-specifi c contrast agent is a rapidly burgeoning imaging modality with high clinical potential ( 17, 21, 22, 27, 28 ) . It has the potential to provide noninvasive insight into the pathophysiologic features and metastasis status of tumors for physicians ( 17 ) and surgeons ( 23, 28 ), and to aid in initial tumor characterization and determination of therapy response, which will be particularly important in patients undergoing molecularly targeted cancer therapy. As mentioned above, it is important for physicians to identify whether the target molecule (e.g., EGFR) is highly expressed in the patients and whether they would benefi t from the targeted therapy (e.g., EGFR inhibition) before and during the treatment. delivery of suitably labeled EGFR ligand to the receptor-positive tumors. IHC assays were carried out to correlate the magnitude of tumor uptake (signal brightness) with the tumor receptor density distribution. IHC staining results ( Fig. 4 ) showed that the MDA-MB-231 tumor was highly EGFR positive (+ + +, n = 5), whilst the MCF-7 tumor had relatively low expression (+, n = 5, P = 0.004). These observations were consistent with the in vitro and in vivo fl uorescence measurements.
Discussion
In the present study, we investigated the feasibility of using Erbitux-Cy5.5 as a probe for noninvasive optical imaging and characterization of EGFR expression in human breast cancer xenografts in mice. Our fi ndings demonstrated the specifi c targeting of Erbitux-Cy5.5 to EGFR both in vitro and in vivo. In addition, our results also indicated that the maximum probe uptake translation of Erbitux-Cy5.5. Although Erbitux is FDA approved for use in humans, the fl uorophore Cy5.5 is not. ICG is similar in molecular structure and is used in gram quantities in humans, without known toxicity. Unfortunately, ICG cannot be easily conjugated to proteins, and it does not offer the fl uorescence intensity of Cy5.5. The approval of a fl uorescent marker that provides intense fl uorescence, although posing no toxic hazard to the patient, is imperative to facilitate clinical experimentation ( 28 ). Because this was a pilot study to demonstrate the feasibility of the imaging technique for characterizing EGFR expression level in vivo, a relatively small number of mice and animal models were used.
Confocal microscopy indicated that the fl uorescence signal was observed in the cytoplasmic region, which may be attributed to the internalization of Erbitux-Cy5.5. As reported recently ( 33 ), rapid receptor In case of no tumor size reduction, it is critical to know whether the lack of response is due to inadequate drug delivery or therapeutic resistance, which may need an increase of dosage or the alteration of therapeutic regimen ( 17 ). In addition, as used in this study, if we could couple the fl uorescent dye to targeted therapeutic agents, the ability to assess the kinetics of the targeted agent in vivo would expedite the process of optimal therapy dosing in individual patients for a maximized therapeutic effect while minimizing drug toxicity ( 29 ).
Fluorescence imaging is readily applicable to human breast tumor evaluation because diffuse optical tomography and spectroscopy with NIR light are currently being evaluated in clinical studies to distinguish the benign from malignant breast lesions and follow tumor response to chemotherapy ( 30-32 ). However, we have to admit that several obstacles exist for the clinical Fig. 3 . In vivo probe kinetics comparison in MDA-MB-231 and MCF-7 tumor models. Fluorescence intensity in the tumor regions after injection of Erbitux-Cy5.5 in mice with MDA-MB-231 tumors (A) and with MCF-7 tumors (C) was signifi cantly higher than that in normal regions ( P <0.001) and changed with time ( P <0.001 both for MDA-MB-231 and MCF-7, B and D). In mice with MDA-MB-231 tumors, the rate of Erbitux-Cy5.5 uptake was higher than that of MCF-7 tumors, with maximum probe uptake dose 1.65-fold higher in MDA-MB-231 than MCF-7 tumors ( P <0.001). All plots are representative of results from the group of mice treated under the same experimental conditions ( n = 5/group). of EGFR expression in breast cancer xenografts in mice models. Although near-infrared contrast agents are still in the experimental stage, once the concerns about the toxicity and optimization of these probes have been addressed, this class of probes could have potential clinical application, including early detection of cancers (primary, recurrent, or metastatic), imageguided receptor-targeted sentinel node biopsies, treatment monitoring, customized dose optimization of targeted therapy, and accelerated drug screening and development.
internalization through circular dorsal ruffl es in plasma membrane may explain why prolonged incubation time may result in endocytosis and internalization, which brought the fl uorescent probes into the cytoplasm and accumulated in the perinuclear region. The internalization of the probes in the cytoplasmic region may also explain the reason why the fl uorescence signals still can be detected in tumors up to 96 hours post injection of the fl uorescent probe without washing out during in vivo NIR imaging studies.
It is interesting to speculate on the reasons why we merely observed an indirect quantitative relationship between in vitro probe binding level and in vivo accumulation level of fl uorescent probes in the corresponding breast cancer xenografts. Besides the difference of EGFR expression level on the tumor cell surface, another possible reason might be that, in the context of tumor-bearing mice, EGFR is ubiquitously expressed in normal tissues (such as liver, kidney, muscles, tumor-adjacent normal tissues), albeit at a much lower level than on tumors, and it is likely that only small concentrations of the fl uorescent probes actually reached the interstitial fl uid bathing the cancer cells after blood circulation. Another factor in the different binding capacities of these tumors may be the differences in the tumor cell sizes. MCF-7 cells are smaller than MDA-MB-231 cells, and for a tumor of a given size, there are a higher number of MCF-7 cells with a higher surface-area-to-volume ratio. Different cancer cell morphology and tissue structure of the two tumors result in the diverse vascular permeability, blood vessel density, and hydrostatic pressure, which may also affect probe delivery to the targets.
In conclusion, this Erbitux-Cy5.5 probe with favorable binding affi nity to EGFR permits quantifi able imaging Fig. 4 . EGFR immunohistochemical assay. A. The strong red-brownish membrane-bound immunostaining on the tumor cells refl ects the abundance of EGFR in MDA-MB-231 (+ + +) (400×). B. The moderate brownish membrane of the MCF-7 tumor cells refl ects weak-to-normal EGFR expression (+) (400×). C. Negative EGFR expression control showed no membranous staining (−) (400×).
